Cytogen launches brachytherapy product

Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed, called BrachySeed Palladium-103. This is the second such offering by Cytogen and DraxImage. The first, BrachySeed I-125 containing radioactive iodine, was launched in 2001. The BrachySeed products complement Cytogen's ProstaScint, a monoclonal antibody-based agent used to image the extent and spread of prostate cancer.